Balanced news tone
News Sentiment
BCYC sentiment intelligence
Bicycle Therapeutics Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
54
Balanced news tone
51 relevant articles
News tone and price action are not far from neutral.
79/100 classification confidence.
directly relevant articles
high-authority source matches
+1.4% over one week, +8.9% over four weeks, trend inactive, and below fair value.
ETFs Investing in Bicycle Therapeutics Plc Sponsored ADR Stocks
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
79/100 classification
One-week reaction
1.4%
Price digesting
Trend fit
Trend inactive
8.9% over four weeks
Fair value
-68.7%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
11
Neutral
38
Negative
2
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
MSN
Direct company coverage
After plunging 20.2% in 4 weeks, here's why the trend might reverse for Bicycle Therapeutics (BCYC)
This article discusses the recent 20.2% decline in Bicycle Therapeutics (BCYC) stock over the past four weeks and explores potential reasons why this downward trend could reverse. It suggests that despite the recent plunge, there might be underlying factors or upcoming events tha
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 15 May 2026 05:40
- Source
- MSN
Market source
Industry context
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
simplywall.st
Industry context
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Market source
Industry context
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Stock Titan
Direct company coverage
Five ASCO studies put Bicycle Therapeutics' cancer drug in focus
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Apr 2026 07:00
- Source
- Stock Titan
Market source
Industry context
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Investing.com
Direct company coverage
Bicycle Therapeutics doses first patient in pancreatic cancer trial
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Apr 2026 07:00
- Source
- Investing.com
Market source
Direct company coverage
Morgan Stanley Updates Bicycle Therapeutics plc (BCYC) Outlook Amid Pipeline Refocus
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 17 Apr 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Wall Street Analysts Believe Bicycle Therapeutics (BCYC) Could Rally 137.88%: Here's is How to Trade
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Apr 2026 07:00
- Source
- Market source
Market source
Direct company coverage
RBC Capital Lowers its Price Target on Bicycle Therapeutics plc (BCYC) to $7 from $11
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 04 Apr 2026 07:00
- Source
- Market source
TradingView
Industry context
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Market source
Direct company coverage
Bicycle Therapeutics (BCYC) Loses 19.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Mar 2026 07:00
- Source
- Market source
simplywall.st
Direct company coverage
Bicycle Therapeutics (BCYC) Quarterly Loss Of US$59.1 Million Tests Growth Focus Narrative
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Mar 2026 07:00
- Source
- simplywall.st
Seeking Alpha
Direct company coverage
Bicycle Therapeutics changes priorities, announces layoffs
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Mar 2026 07:00
- Source
- Seeking Alpha
Market source
Direct company coverage
Bicycle Therapeutics (BCYC) Appoints Travis Thompson as CFO Following Leadership Transitions
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Mar 2026 07:00
- Source
- Market source
simplywall.st
Direct company coverage
We Think Bicycle Therapeutics (NASDAQ:BCYC) Needs To Drive Business Growth Carefully
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 05 Feb 2026 08:00
- Source
- simplywall.st
simplywall.st
Direct company coverage
Don't Ignore The Insider Selling In Bicycle Therapeutics
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jan 2026 08:00
- Source
- simplywall.st
Market source
Direct company coverage
Bicycle Therapeutics plc (NASDAQ:BCYC) has caught the attention of institutional investors who hold a sizeable 45% stake
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 12 Sep 2025 07:00
- Source
- Market source
simplywall.st
Direct company coverage
Analysts Just Slashed Their Bicycle Therapeutics plc (NASDAQ:BCYC) EPS Numbers
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 Aug 2025 07:00
- Source
- simplywall.st
citybiz
Direct company coverage
Bicycle Therapeutics Announces $555 Million Private Placement Equity Financing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 May 2024 07:00
- Source
- citybiz